Literature DB >> 24365582

Value of critical flicker frequency and psychometric hepatic encephalopathy score in diagnosis of low-grade hepatic encephalopathy.

Gerald Kircheis1, Norbert Hilger2, Dieter Häussinger3.   

Abstract

BACKGROUND & AIMS: Critical flicker frequency (CFF) and psychometric hepatic encephalopathy score (PHES) analyses are widely used to diagnose hepatic encephalopathy (HE), but little is known about their value in the diagnosis of low-grade HE.
METHODS: The diagnostic values of CFF and PHES were compared using a computerized test battery and West Haven criteria as reference. We performed CFF analysis on 559 patients with cirrhosis and 261 without (controls). Of these 820 patients, 448 were evaluated using a modified PHES system and 148 were also evaluated using the conventional PHES system.
RESULTS: CFF distinguished between patients with overt HE and without minimal or overt HE in the entire study population with 98% sensitivity and 94% specificity and in the subgroup of patients who were evaluated by conventional PHES with 97% sensitivity and 100% specificity. Conventional PHES identified patients with overt HE with 73% sensitivity and 89% specificity. CFF distinguished between patients with and without minimal HE with only 37% sensitivity but 94% specificity (entire study population). In the subgroup of patients evaluated by conventional PHES, CFF distinguished between patients with and without minimal HE with 22% sensitivity and 100% specificity; these values were similar to those for conventional PHES (30% sensitivity and 89% specificity). The modified PHES distinguished between patients with and without minimal HE with 49% sensitivity and 74% specificity. The diagnostic agreement values between CFF and conventional or modified PHES in patients with minimal HE were only 54% or 47%, respectively.
CONCLUSIONS: In an analysis of patients with cirrhosis and controls, CFF distinguished between patients with overt HE and without minimal or overt HE. PHES testing produced a statistically significant difference among groups, but there was considerable overlap between controls and patients with overt HE. PHES, CFF, and a combination of PHES and CFF could not reliably distinguish patients with minimal HE from controls or those with overt HE.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Advanced Liver Disease; Cognitive Function; MHE; Neuropsychology

Mesh:

Year:  2013        PMID: 24365582     DOI: 10.1053/j.gastro.2013.12.026

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  18 in total

Review 1.  Advances in psychometric tests for screening minimal hepatic encephalopathy: From paper-and-pencil to computer-aided assessment.

Authors:  Ming Luo; Ping Ma; Lei Li; Wu-Kui Cao
Journal:  Turk J Gastroenterol       Date:  2019-05       Impact factor: 1.852

Review 2.  PET and MR imaging of neuroinflammation in hepatic encephalopathy.

Authors:  Yun Yan Su; Gui Fen Yang; Guang Ming Lu; Shawn Wu; Long Jiang Zhang
Journal:  Metab Brain Dis       Date:  2014-12-17       Impact factor: 3.584

3.  Contemporary Understanding and Management of Overt and Covert Hepatic Encephalopathy.

Authors:  Meghan NeSmith; Joseph Ahn; Steven L Flamm
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-02

4.  Low visual cortex GABA levels in hepatic encephalopathy: links to blood ammonia, critical flicker frequency, and brain osmolytes.

Authors:  Georg Oeltzschner; Markus Butz; Thomas J Baumgarten; Nienke Hoogenboom; Hans-Jörg Wittsack; Alfons Schnitzler
Journal:  Metab Brain Dis       Date:  2015-09-11       Impact factor: 3.584

5.  Role of Brain Biomarkers S-100-Beta and Neuron-Specific Enolase for Detection and Follow-Up of Hepatic Encephalopathy in Cirrhosis before, during and after Treatment with L-Ornithine-L-Aspartate.

Authors:  Hendrik Strebel; Bernhard Haller; Maximilian Sohn; Wolfgang Schepp; Felix Gundling
Journal:  GE Port J Gastroenterol       Date:  2020-04-21

Review 6.  New technologies - new insights into the pathogenesis of hepatic encephalopathy.

Authors:  Luisa Baker; Bernard Lanz; Fausto Andreola; Javier Ampuero; Anisha Wijeyesekera; Elaine Holmes; Nicolaas Deutz
Journal:  Metab Brain Dis       Date:  2016-09-30       Impact factor: 3.584

7.  Screening for minimal hepatic encephalopathy in patients with cirrhosis by cirrhosis-related symptoms and a history of overt hepatic encephalopathy.

Authors:  Emi Yoshimura; Tatsuki Ichikawa; Hisamitsu Miyaaki; Naota Taura; Satoshi Miuma; Hidataka Shibata; Takuya Honda; Fuminao Takeshima; Kazuhiko Nakao
Journal:  Biomed Rep       Date:  2016-06-13

Review 8.  Qualifying and quantifying minimal hepatic encephalopathy.

Authors:  Marsha Y Morgan; Piero Amodio; Nicola A Cook; Clive D Jackson; Gerald Kircheis; Mette M Lauridsen; Sara Montagnese; Sami Schiff; Karin Weissenborn
Journal:  Metab Brain Dis       Date:  2015-09-28       Impact factor: 3.584

9.  Covert hepatic encephalopathy: elevated total glutathione and absence of brain water content changes.

Authors:  Georg Oeltzschner; Markus Butz; Frithjof Wickrath; Hans-Jörg Wittsack; Alfons Schnitzler
Journal:  Metab Brain Dis       Date:  2015-11-12       Impact factor: 3.584

10.  Determination of Turkish norms of psychometric tests for diagnosing minimal hepatic encephalopathy and proposal of a high sensitive screening test battery.

Authors:  Burak Özbaş; Onur Keskin; Hartmut Hecker; Irfan Karahan; Cansu Özbaş; Çağdaş Kalkan; Aysun Kartal; Fatih Oğuz Önder; Burcu Kahveci Öncü; Genco Gençdal; Murat Akyildiz; Fulya Günşar; Ramazan Idilman; Karin Weissenborn; Ömer Özütemiz; Cihan Yurdaydin
Journal:  Hepatol Int       Date:  2021-06-03       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.